Clinical efficacy of sildenafil in treatment of pulmonary arterial hypertension in dogs

Journal of Veterinary Internal Medicine

Volumn 24, Issue 4, 2010, Pages 850-854

  Brown, A J ^a   Davison, E ^b   Sleeper, M M ^b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Echocardiography; Heart disease; Hemodynamics; Pulmonary disease

Indexed keywords

ANIMALIA; CANIS FAMILIARIS;

PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SILDENAFIL; SULFONE; VASODILATOR AGENT;

ANIMAL; ANIMAL DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOG; DOUBLE BLIND PROCEDURE; FEMALE; MALE; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL;

ANIMALS; CROSS-OVER STUDIES; DOGS; DOUBLE-BLIND METHOD; FEMALE; HYPERTENSION, PULMONARY; MALE; PIPERAZINES; PURINES; SULFONES; VASODILATOR AGENTS;

EID: 77956644636     PISSN: 08916640     EISSN: 19391676     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2010.0517.x     Document Type: Article

References (22)

1. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997;336:111-117.
2. Johnson L, Boon J, Orton EC. Clinical characteristics of 53 dogs with Doppler-derived evidence of pulmonary hypertension: 1992-1996. J Vet Intern Med 1999;13:440-447.
3. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343-349.
4. Bach JF, Rozanski EA, MacGregor J, et al. Retrospective evaluation of sildenafil citrate as a therapy for pulmonary hypertension in dogs. J Vet Intern Med 2006;20:1132-1135.
5. Galie N, Seeger W, Naeije R, et al. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:81S-88S.
6. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-2157.
7. Michelakis E, Tymchak W, Lien D, et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: Comparison with inhaled nitric oxide. Circulation 2002;105:2398-2403.
8. Pepke-Zaba J, Gilbert C, Collings L, et al. Sildenafil improves health-related quality of life in patients with pulmonary arterial hypertension. Chest 2008;133:183-189.
9. Sastry BK, Narasimhan C, Reddy NK, et al. Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 2004;43:1149-1153.
10. Suntharalingam J, Treacy CM, Doughty NJ, et al. Longterm use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Chest 2008;134:229-236.
11. Takimoto E, Champion HC, Li M, et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005;11:214-222.
12. Wharton J, Strange JW, Moller GM, et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 2005;172:105-113.
13. Kellum HB, Stepien RL. Sildenafil citrate therapy in 22 dogs with pulmonary hypertension. J Vet Intern Med 2007;21:1258-1264.
14. Hansen BD, Lascelles BD, Keene BW, et al. Evaluation of an accelerometer for at-home monitoring of spontaneous activity in dogs. Am J Vet Res 2007;68:468-475.
15. Dow C, Michel KE, Love M, et al. Evaluation of optimal sampling interval for activity monitoring in companion dogs. Am J Vet Res 2009;70:444-448.
16. Simonneau G, Rubin LJ, Galie N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: A randomized trial. Ann Intern Med 2008;149:521-530.
17. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: A randomised controlled trial. Lancet 2002;360:895-900.
18. Lepore JJ, Maroo A, Bigatello LM, et al. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: Combined administration with inhaled nitric oxide. Chest 2005;127:1647-1653.
19. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000;161:487-492.
20. Boddy KN, Roche BM, Schwartz DS, et al. Evaluation of the six-minute walk test in dogs. Am J Vet Res 2004;65:311-313.
21. Freeman LM, Rush JE, Farabaugh AE, et al. Development and evaluation of a questionnaire for assessing health-related quality of life in dogs with cardiac disease. J Am Vet Med Assoc 2005;226:1864-1868.
22. Atkinson KJ, Fine DM, Thombs LA, et al. Evaluation of pimobendan and N-terminal probrain natriuretic peptide in the treatment of pulmonary hypertension secondary to degenerative mitral valve disease in dogs. J Vet Intern Med 2009;23:1190-1196.